You are here
EULAR 2019 begins today in Madrid and features over 2000 presentations. After an initial review of titles and abstracts, I’ve compiled a hit list of presentations of interest to me and hopefully other practicing rheumatologists.
EULAR will be rolling out many new “guidelines” reports including those addressing rheumatoid arthritis (RA) treatment; immune-related adverse events with checkpoint inhibitors, Sjogrens syndrome and more.
Late-breaking abstracts will be presented on Saturday morning (June 15th) and will include reports on filgotinib (Finch3), secukinumab (FUTURE 5), HLA-DRB1 alleles and responses to Abatacept or Adalimumab, Ultra-low dose rituximab and more.
Here are some abstracts I’ll be watching (with links to EULAR Abstract site). Which of these interests you?
Two regimens of Rituximab in Scleroderma associated interstitial lung disease
Appears to improve Lung function
KAWAKINRA study: A pilot trial of anakinra in patients with IVIg-resistant Kawasaki disease
Rare disorder with good results in refractory disease. Dosing issues?
Randomized, double blind, placebo controlled trial of Steroids in Hand OA
Looks like it works? But what about adverse effects?
Riociguat in SSc associated ILD
Anti-fibrotic drug shows some benefit in SSc lung disease
TOLEDEO study – Spacing ABA or TCZ to find the lowest effective dose in RA patients
Looks like less drug therapy carried a high risk of failure
Registry data on long-term outcomes and treatment efficacy in the TRAPS patients
IL-1 inhibitors much more effective than etanercept
Statins reduce relapse rates in Takayasu arteritis
A novel adjunctive therapy?
Fenebrutinib vs. Adalimumab in RA
BTK inhibitor works in MTX- & TNF-IR patients
Implated Vagal nerve stimulator in rheumatoid arthritis
Only 14 patients but novel, and looks effective
Tildrakizumab in active PsA patients
Data on 3rd IL-23 inhibitor
Maxmize Study: Secukinumab on Axial Manifestations in Psoriatic arthritis
Secukinumb works on the Axial outcomes of PsA pts with Spondylitis
Measures of psoriasis severity and the risk of PsA
Skin severity predicts risk of PsA
Characterization of psoriatic arthritis and nail psoriasis
CORRONA - Nail disease predicts worse disease activity
Ultrasound application in Extracranial GCA
Axillary US correlates with PET findings
EULAR recommendations for the management of irAE
One of many EULAR recommendations at this meeting
EULAR Recommendations for the Management of Sjogrens